ESM1 and systemic lupus erythematosus: Our findings suggest that serum endocan is associated with disease activity; however, further clinical studies involving larger patient cohorts are required to better elucidate the role of serum endocan and other glycocalyx-related biomarkers in cardiovascular risk assessment among SLE patients.